Literature DB >> 29898589

Selective peripheral neurolysis using high frequency ultrasound imaging: a novel approach in the treatment of spasticity.

Bayram Kaymak1, Murat Kara2, Eda Gürçay3, Gülümser Aydin4, Levent Özçakar1.   

Abstract

BACKGROUND: Chemoneurolysis is used to treat focal spasticity in patients with upper motor neuron syndrome. CASE REPORT: Neurolytic substances (phenol/alcohol) injected nearby/in the main trunk of peripheral nerves can cause not only motor but also cutaneous nerves destruction. The latter is thought to be responsible for considerable side effects such as dysesthesia and paresthesia. During injections, targeting the primary motor branches originating from the main trunk while sparing cutaneous nerves will result in decrease/elimination of these side effects and better clinical improvement. CLINICAL REHABILITATION IMPACT: We suggest that high frequency ultrasound enabling the physician to scan peripheral nerves and their primary branches can be useful to perform this selective peripheral neurolysis in the treatment of spasticity.

Entities:  

Year:  2018        PMID: 29898589     DOI: 10.23736/S1973-9087.18.05295-4

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  2 in total

1.  Comment on Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins 2017, 10, 18-Quintessential Use of Ultrasound Guidance for Botulinum Toxin Injections-Muscle Innervation Zone Targeting Revisited.

Authors:  Bayram Kaymak; Fevziye Ünsal Malas; Murat Kara; Arzu Yağız On; Levent Özçakar
Journal:  Toxins (Basel)       Date:  2018-09-28       Impact factor: 4.546

2.  Localization of nerve entry points and the center of intramuscular nerve-dense regions in the adult pectoralis major and pectoralis minor and its significance in blocking muscle spasticity.

Authors:  Yanrong Li; Meng Wang; Shaohua Tang; Xiankun Zhu; Shengbo Yang
Journal:  J Anat       Date:  2021-06-27       Impact factor: 2.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.